{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RhIGF-1",
    "query": {
      "intervention": "RhIGF-1"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 16,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RhIGF-1&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-16T01:59:58.576Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01777542",
      "title": "Treatment of Rett Syndrome With Recombinant Human IGF-1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rett Syndrome"
      ],
      "interventions": [
        {
          "name": "Recombinant Human Insulin Growth Factor 1 (rhIGF-1)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "10 Years",
        "sex": "FEMALE",
        "summary": "2 Years to 10 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2013-01",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2018-03-26",
      "last_synced_at": "2026-09-16T01:59:58.576Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01777542"
    },
    {
      "nct_id": "NCT00571727",
      "title": "Long-Term Treatment With rhIGF-1 in GHIS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Growth Hormone Insensitivity Syndrome"
      ],
      "interventions": [
        {
          "name": "mecasermin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 92,
      "start_date": "1991-05-20",
      "completion_date": "2011-12-15",
      "has_results": true,
      "last_update_posted_date": "2023-07-06",
      "last_synced_at": "2026-09-16T01:59:58.576Z",
      "location_count": 1,
      "location_summary": "Brisbane, California",
      "locations": [
        {
          "city": "Brisbane",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00571727"
    },
    {
      "nct_id": "NCT00572156",
      "title": "rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Insulin-like Growth Factor-1 Deficiency"
      ],
      "interventions": [
        {
          "name": "NutropinAq® (Somatropin [rDNA origin])",
          "type": "DRUG"
        },
        {
          "name": "Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2007-12",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2023-03-30",
      "last_synced_at": "2026-09-16T01:59:58.576Z",
      "location_count": 1,
      "location_summary": "Brisbane, California",
      "locations": [
        {
          "city": "Brisbane",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00572156"
    },
    {
      "nct_id": "NCT00720122",
      "title": "Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Disorder of Bone Density and Structure, Unspecified"
      ],
      "interventions": [
        {
          "name": "Recombinant human insulin like growth factor-1 (rhIGF-1)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "26 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 26 Years · Female only"
      },
      "enrollment_count": 28,
      "start_date": "2008-07",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2021-11-18",
      "last_synced_at": "2026-09-16T01:59:58.576Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00720122"
    },
    {
      "nct_id": "NCT00001669",
      "title": "A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "rhIGF-1 (CEP-151)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 15,
      "start_date": "1997-07",
      "completion_date": "2000-04",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-09-16T01:59:58.576Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001669"
    },
    {
      "nct_id": "NCT00684957",
      "title": "Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Growth Hormone Deficiency"
      ],
      "interventions": [
        {
          "name": "Recombinant Human Growth Hormone",
          "type": "DRUG"
        },
        {
          "name": "Recombinant Human IGF-1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "25 Years to 65 Years · Male only"
      },
      "enrollment_count": 5,
      "start_date": "2008-01",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2024-07-17",
      "last_synced_at": "2026-09-16T01:59:58.576Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00684957"
    },
    {
      "nct_id": "NCT00516386",
      "title": "Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anorexia Nervosa"
      ],
      "interventions": [
        {
          "name": "RhIGF-1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 18 Years · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2007-03",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2021-11-18",
      "last_synced_at": "2026-09-16T01:59:58.576Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00516386"
    },
    {
      "nct_id": "NCT01096784",
      "title": "IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retinopathy of Prematurity (ROP)"
      ],
      "interventions": [
        {
          "name": "rhIGF-I/rhIGFBP-3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "1 Day",
        "sex": "ALL",
        "summary": "Up to 1 Day"
      },
      "enrollment_count": 121,
      "start_date": "2010-06-18",
      "completion_date": "2016-03-30",
      "has_results": true,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-09-16T01:59:58.576Z",
      "location_count": 8,
      "location_summary": "Mobile, Alabama • Irvine, California • Augusta, Georgia + 5 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01096784"
    },
    {
      "nct_id": "NCT01301183",
      "title": "Effects of Anorexia Nervosa on Peak Bone Mass",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anorexia Nervosa"
      ],
      "interventions": [
        {
          "name": "RhIGF-1 with transdermal 17-beta estradiol",
          "type": "DRUG"
        },
        {
          "name": "Placebo and transdermal 17-beta estradiol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "22 Years",
        "sex": "FEMALE",
        "summary": "14 Years to 22 Years · Female only"
      },
      "enrollment_count": 75,
      "start_date": "2011-02",
      "completion_date": "2020-03",
      "has_results": true,
      "last_update_posted_date": "2021-07-13",
      "last_synced_at": "2026-09-16T01:59:58.576Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01301183"
    },
    {
      "nct_id": "NCT00351221",
      "title": "Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Noonan Syndrome"
      ],
      "interventions": [
        {
          "name": "rhIGF-1/rhIGFBP-3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insmed Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "2 Years to 16 Years"
      },
      "enrollment_count": 24,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-03-30",
      "last_synced_at": "2026-09-16T01:59:58.576Z",
      "location_count": 2,
      "location_summary": "New Hyde Park, New York • Columbus, Ohio",
      "locations": [
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00351221"
    }
  ]
}